Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses [7] (multiple letters)

David Marin, John M. Goldman, Eduardo Olavarria, Jane F. Apperley, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalLetterpeer-review

62 Scopus citations
Original languageEnglish (US)
Pages (from-to)2702-2704
Number of pages3
JournalBlood
Volume102
Issue number7
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this